IP02-05: Cost-Effectiveness Analysis of Sasanlimab plus BCG for High-Risk Non-muscle Invasive Bladder Cancer (NMIBC): Analysis From CREST
Friday, May 15, 2026 7:00 AM to 9:00 AM · 1 hr. 59 min. (America/New_York)
146A
Abstract
Log in
See all the content and easy-to-use features by logging in or registering!